Tag Archives: Merck

Fosamax litigation ready for next step in bellwether cases

Six years after the first Fosamax lawsuit was filed, litigation over the osteoporosis drug is about to start a new chapter. The suits against Merck, the drug’s manufacturer, fall into two categories: plaintiffs alleging they suffer from osteonecrosis, or jaw ...

Read More »

Merck settles Vytorin shareholder class action suit

Merck will pay $5.1 million in attorney fees and institute corporate reforms under the terms of a settlement of a shareholder class action concerning the alleged suppression of negative clinical test results for the blockbuster anti-cholesterol drug Vytorin.

Read More »